Thymosin α₁‐ and Ulinastatin‐Based Immunomodulatory Strategy for Sepsis Arising from Intra‐Abdominal Infection Due to Carbapenem‐Resistant Bacteria

Abstract

The trial was registered with the Chinese State Food and Drug Administration (Peking Science and Technology Development Plan, 2002[641]), (registration number 2007Y0211).